Amid the surge of new technologies in healthcare, such as the rise of artificial intelligence and the promise of personalised medicine, the UK’s National Health Service (NHS) has been slow to keep up.
That may be about to change Read more
While on holiday this year my kids provided a perfect illustration of how sometimes tactics get confused with strategy and the power of a true change in strategy. Read more
Over the past couple of months we have been sharing some insights into our Delivering ChangeTM planning model. In the final blog of this series we delve into our ‘Library of Change’. Read more
We work in the area of mental health for one of our clients, which means we can list off the names of prominent thinkers in the field, the main medical meetings, and the DSM-V diagnostic criteria for depression. But, what can be harder to talk about is when someone in our close-knit team is affected by poor mental health. Read more
In this third blog in our series about Delivering Change we provide a brief overview of what CHC means when we talk about change.
‘Change’ has become a buzzword in our industry but more often than not, this ‘change’ only ever relates to behaviour change – changing the prescribing habits of healthcare professionals or changing people’s engagement in their own health. At CHC, we wanted to take this one step further and be more specific about ‘change’. Read more
We’ve been talking a lot about Delivering ChangeTM as of late, and one of the key components of the Delivering ChangeTM process is to seek external sources of inspiration to help drive unexpected creative approaches in our work. With that in mind, three of the team wandered over to the ExCel London for The New Scientist Live 2018. This year, in particular, we were impressed by the various methods of communication. Read on for some of our highlights:
In our recent press release announcing the launch of our Delivering ChangeTM planning model, we mentioned how we were inspired by Theories of Change.
In this 3 minute blog we’ll provide a some background on theories of change; what they are, how they work and how we’ve built on this to create CHC’s unique model.
On 1st August we launched our new Delivering ChangeTM planning model and in this short blog we wanted to outline the two key reasons why.
We’ve talked about Delivering Change as part of the CHC brand for a couple of years now and even before that, it was a founding principle of the company.
Artificial intelligence (AI) technology is quickly advancing to improve the speed of diagnosis, predict the success of drug discoveries and provide virtual assistance to patients.1 The benefits of this technology (including convenience, improved patient treatment, cost savings and reduction in human errors) makes AI incredibly desirable to over-stretched and budget-restricted healthcare systems, especially the NHS. Read more
Personalised, precision, stratified, whatever you call tailored healthcare it has been a key point of discussion now for many years. There is undoubtedly a slow but definite shift towards this type of healthcare and a huge milestone was reached last week. Genomics England announced it had sequenced its 100,000th individual genome and had therefore completed the 100,000 genome project1.
At Clark Health, we are always looking for the next “big thing” in healthcare. With several neuroscience graduates in our team and our broad experience working on neurology products, it’s an area we like to keep an eye on. Like many other disease areas, breakthroughs in the world of neuroscience are incredibly rare, so when a Huntington’s disease treatment made new ground earlier this year1, it created waves of excitement and we’ve been watching this space ever since. Read more
Recently, there have been a number of reports and studies exploring the potential therapeutic applications of currently illicit drugs. Cannabis is breaking down barriers in the treatment of certain types of epilepsy in the UK and a marketing application for an intranasal esketamine spray has been submitted to the EMA for treatment-resistant major depressive disorder.
Currently available antidepressants, such as SSRIs, are used collectively to treat major depressive disorder, anxiety and other mood disorders. They have been shown to lack substantial efficacy in all patient populations and are renowned for having a delayed onset of action (Penn and Tracy, 2012). Working in the area of mental health at CHC, coupled with an interest to find out more, we ventured further into a current avenue of research that looked more and more curious…